Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
soup, your on the mark plus good research
Hale, I have my ways of knowing, plus the response from someone here tells me I was right.
Looks like the poodles are off the leash again ... the MMs must be short.
Ignore the tosspot. How do you know investopian has sold? They were still pumping an hour ago.
Thanks Aim, maybe I'll not bother sharing research as I find it. You didn't seem to mind the patent update on Friday night.
I look forward to your contributions.
Rich coming from you Soup feel deeply sorry for a man who’s been in stock that’s seen such a massive drop
Investopian on twitter has sold out now, time for the sp to move up.
Goup, its up 8.5%.... whats the problem?
Good points
Lenigas would have rns all over this
The patents, tr1 and ox,
If our management read this you really are crap at commication
"patience guy’s Rome wasn’t built in a day!"
Wasn't the world built in six?
007] It has been reported that tranilast has the ability to induce or enhance neurogenesis and, therefore, could be used as an agent to treat neuronal conditions such as cerebral ischernia, glaucoma, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, neurodegenerative trinucleotide repeat disorders, neurodegenerative lyosomal storage diseases, spinal cord injury and trauma, dementia, schizophrenia and peripheral neuropathy (A. Schneider.
EP2030617).
[008] Tranilast's beneficial properties have been reported to have utility in several ocular conditions. Tranilast is currently approved in Japan and Korea for the treatment of allergic conjunctivitis. W02010137681 claims the use of tranilast as a prophylactic or therapeutic agent for the treatment of retinal diseases. The anti-fibrotic properties of tranilast have been reported to be of benefit in maintaining the filtering blob during glaucoma surgery and this has been demonstrated in a pilot study in humans (E. Chihara..1 Glaucoma. 1999; 11(2): 127-133).
006] As has recently been demonstrated, in-vitro and in-vivo, tranilast also possesses an anti-tumor action. Tranilast has been shown to inhibit the proliferation, apoptosis and migration of several cell lines including breast cancer (R. Chakrabarti. Anticancer Drugs.
2009 Jun; 20(5): 334-45) and prostate cancer (S. Sato. Prostate. 2010 Feb; 70(3): 229-38) cell lines.
In a study of mammary carcinoma in mice tranilast was found to produce a significant reduction in metastasis (R.
Chakrabarti. Anticancer Drugs. 2009 Jun; 20(5): 334-45). In a pilot study in humans, tranilast was shown to have the potential to improve the prognosis of patients with advanced castration-resistant prostate cancer (K. lzurni. Anticancer Research. 2010 jul; 30: 73077-81).
Has anyone actually read it ? It’s positive and full of information
Description
Tranilast Compositions and Cocrystals Cross Reference to Related Applications [001] This application claims priority to US Patent Application 61/618,639, filed March 30, 2012;
the disclosure of which is incorporated herein by reference.
patience guy’s Rome wasn’t built in a day!
Wilfred, because its not new, its Canada only.
In my opinion the next rns will be the
Initiation of the feasibility studies on NXP002 in Q2 2021
As per expected news flow from the Allenby report I think they will mention the updated patent approval in this announcement
Look at the date of the grant. Its 3 weeks ago. Any RNS would have been issued already.
We don't rely on the company for regulatory news here, we have Soupdragon
This is nfx
Why no RNS?
Its the twitter crowd getting excited about something they don't understand. There won't be an RNS for the patent.
Ox will be the next news.
I wonder if this is another P&D... Anyhow small rises like this won't interest me until we are 9p plus
Poor communication as usual, they really need to sort out the PR. Response to emails are awful too might as well be an out of office.
Still being disappointed here however as usual there's no way I'm selling as the potential upside is huge and worth the pain
Shame no RNS on this. This is really good news as Soup has shown it takes a really long time to get that 'Accepted' patent in place. Seems other companies on here offer an RNS on much less worthy news. Hope things get better!